Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:25:57 EDT Tue 09 Jun 2026
Enter Symbol
or Name
USA
CA



Q:ONCY - ONCOLYTICS BIOTECH INC - https://www.oncolyticsbiotech.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ONCY - Q7.00.77·0.91180.10.84+0.00380.51,180.68114,4030.83  0.86  0.821.51  0.370719:58:38Jun 0215 min RT 2¢

Recent Trades - Last 10 of 4403
Time ETExPriceChangeVolume
19:58:38Q0.8251-0.01111
18:49:08Q0.8370.00083
18:19:12Q0.84150.0053700
18:14:15Q0.84150.005310
18:03:03Q0.84890.01273
17:32:21Q0.84890.01278
16:49:08Q0.84880.012640
16:44:09Q0.84890.0127250
16:43:27Q0.840.003861
16:24:54Q0.840.003820

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-06-02 09:00U:ONCYNews ReleaseOncolytics Biotech(TM) Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer
2026-06-01 09:00U:ONCYNews ReleaseOncolytics Biotech(TM) Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
2026-05-26 09:00U:ONCYNews ReleaseFrom Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story
2026-05-22 09:00U:ONCYNews ReleaseOncolytics Biotech(TM) to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors
2026-05-14 15:10U:ONCYSEDAR Interim Financial StatementsSEDAR Interim MD & A
2026-05-14 10:55U:ONCYNews Release"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
2026-05-04 09:00U:ONCYNews ReleaseOncolytics Biotech(TM) Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
2026-04-27 08:10U:ONCYNews ReleaseOncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
2026-04-06 09:00U:ONCYNews ReleaseOncolytics Biotech(TM) Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
2026-04-01 09:00U:ONCYNews ReleaseOncolytics Biotech(TM) Completes Domicile Change to the United States
2026-03-30 06:33U:ONCYSEDAR Annual ReportSEDAR Annual Report
2026-03-30 06:29U:ONCYSEDAR Audited Annual Financial StatementsSEDAR MD & A
2026-03-19 11:00U:ONCYNews ReleaseThe Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
2026-03-19 09:00U:ONCYNews ReleaseOncolytics Biotech(TM) to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
2026-03-02 09:00U:ONCYNews ReleaseOncolytics Biotech(TM) Launches Randomized Colorectal Cancer Study
2026-02-24 09:00U:ONCYNews ReleaseOncolytics Biotech(TM) to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer
2026-02-17 10:48U:ONCYNews ReleaseRegistration Momentum Builds Across the Oncology Pipeline
2026-02-05 09:26U:ONCYNews ReleaseThe $71 Billion Cancer Shift: Why The FDA Is Speeding Up
2026-02-04 08:50U:ONCYNews ReleaseOncolytics Biotech(TM) Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
2026-01-26 10:14U:ONCYNews ReleaseTHE RESILIENCE DOCTRINE: 5 Assets Securing the 2026 Sovereign Stack